These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 19926583)
1. Absence of the BRAF mutation in HBME1+ and CK19+ atypical cell clusters in Hashimoto thyroiditis: supportive evidence against preneoplastic change. Nasr MR; Mukhopadhyay S; Zhang S; Katzenstein AL Am J Clin Pathol; 2009 Dec; 132(6):906-12. PubMed ID: 19926583 [TBL] [Abstract][Full Text] [Related]
2. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Kim KH; Suh KS; Kang DW; Kang DY Pathol Int; 2005 Sep; 55(9):540-5. PubMed ID: 16143028 [TBL] [Abstract][Full Text] [Related]
3. Solid cell nests, papillary thyroid microcarcinoma, and HBME1. Seethala RR; Chiosea SI Am J Clin Pathol; 2010 Jul; 134(1):169-70. PubMed ID: 20551283 [No Abstract] [Full Text] [Related]
4. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784 [TBL] [Abstract][Full Text] [Related]
5. BRAF mutation is unusual in chronic lymphocytic thyroiditis-associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis. Sargent R; LiVolsi V; Murphy J; Mantha G; Hunt JL Endocr Pathol; 2006; 17(3):235-41. PubMed ID: 17308360 [TBL] [Abstract][Full Text] [Related]
6. BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns. Jakubowski M; Hunt JL Am J Surg Pathol; 2009 Nov; 33(11):1590-3. PubMed ID: 19738460 [TBL] [Abstract][Full Text] [Related]
7. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161 [TBL] [Abstract][Full Text] [Related]
8. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis]. Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941 [No Abstract] [Full Text] [Related]
9. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Kim SK; Kim DL; Han HS; Kim WS; Kim SJ; Moon WJ; Oh SY; Hwang TS Diagn Mol Pathol; 2008 Jun; 17(2):118-25. PubMed ID: 18382358 [TBL] [Abstract][Full Text] [Related]
10. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Chuang TC; Chuang AY; Poeta L; Koch WM; Califano JA; Tufano RP Head Neck; 2010 Feb; 32(2):229-34. PubMed ID: 19626635 [TBL] [Abstract][Full Text] [Related]
11. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Wang Y; Ji M; Wang W; Miao Z; Hou P; Chen X; Xu F; Zhu G; Sun X; Li Y; Condouris S; Liu D; Yan S; Pan J; Xing M Endocr Relat Cancer; 2008 Mar; 15(1):183-90. PubMed ID: 18310286 [TBL] [Abstract][Full Text] [Related]
12. Encapsulated papillary oncocytic neoplasms of the thyroid: morphologic, immunohistochemical, and molecular analysis of 18 cases. Woodford RL; Nikiforov YE; Hunt JL; Bellizzi AM; Zhang X; Mills SE; Stelow EB Am J Surg Pathol; 2010 Nov; 34(11):1582-90. PubMed ID: 20924280 [TBL] [Abstract][Full Text] [Related]
13. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma. Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation. Atik E; Guray M; Gunesacar R; Ozgur T; Canda T Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099 [TBL] [Abstract][Full Text] [Related]
15. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523 [TBL] [Abstract][Full Text] [Related]
16. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Santarpia L; Sherman SI; Marabotti A; Clayman GL; El-Naggar AK Hum Pathol; 2009 Jun; 40(6):827-33. PubMed ID: 19200582 [TBL] [Abstract][Full Text] [Related]
17. BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma. Chang H; Lee H; Yoon SO; Kim H; Kim A; Kim BH Hum Pathol; 2012 Jan; 43(1):89-95. PubMed ID: 21774961 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Scognamiglio T; Hyjek E; Kao J; Chen YT Am J Clin Pathol; 2006 Nov; 126(5):700-8. PubMed ID: 17050067 [TBL] [Abstract][Full Text] [Related]
19. Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma. Kim HS; Kim JO; Lee DH; Lee HC; Kim HJ; Kim JH; Jang YS; Lee JM; Kim SY; Kim YS Oncol Rep; 2011 Jun; 25(6):1639-44. PubMed ID: 21431280 [TBL] [Abstract][Full Text] [Related]
20. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value]. Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]